Agilent
Agilent Technologies Gains Expanded IVDR Certification for PD-L1 CDx
The test has been certified for use in the EU to help guide the treatment of early-stage non-small cell lung cancer and previously untreated advanced melanoma.
Agilent Reports Fiscal Q1 Revenues Rise 1 Percent, Cuts Full-Year Guidance
The Santa Clara, California-based firm said that its diagnostics and life sciences revenues rose 4 percent year over year.
In Brief This Week: T2 Biosystems, Danaher, Agilent, Lucid Diagnostics, More
News items for the week of Feb. 17, 2025.
Agilent Technologies Nabs IVDR Certification for PD-L1 CDx
The PD-L1 IHC 28-8 PharmDx test is used to provide information on PD-L1 expression as a biomarker for patient response to therapies containing anti-PD-1 antibodies.
The McGill University team is advancing a test, dubbed DOvEEgene, which sequences DNA from a uterine brush sample to detect cancer-associated mutations.
Nov 25, 2024
Agilent Reorganizes Business Units
Sep 6, 2024
Agilent to Offer $1.2B in Senior Notes
Jun 26, 2024
Agilent Laying off 184 California Employees
Feb 27, 2024